Home > Research > Publications & Outputs > Serum CA72-4 is specifically elevated in gout p...

Electronic data

  • RHE-19-1392.R2_Proof_hi

    Rights statement: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The definitive publisher-authenticated version Xueshan Bai, Mingshu Sun, Yuwei He, Ruhua Liu, Lingling Cui, Can Wang, Fang Wan, Ming Wang, Xinde Li, Hailong Li, Xinjiang Wu, Changgui Li, Serum CA72-4 is specifically elevated in gout patients and predicts flares, Rheumatology, , keaa046, https://doi.org/10.1093/rheumatology/keaa046 is available online at:

    Accepted author manuscript, 1.95 MB, PDF document

    Embargo ends: 22/02/21

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Text available via DOI:

View graph of relations

Serum CA72-4 is specifically elevated in gout patients and predicts flares

Research output: Contribution to journalJournal article

E-pub ahead of print
  • Xueshan Bai
  • Mingshu Sun
  • Yuwei He
  • Ruhua Liu
  • Lingling Cui
  • Can Wang
  • Fang Wan
  • Ming Wang
  • Xinde Li
  • Hailong Li
  • Xinjiang Wu
  • Changgui Li
Close
<mark>Journal publication date</mark>22/02/2020
<mark>Journal</mark>Rheumatology
Number of pages9
Publication statusE-pub ahead of print
Early online date22/02/20
Original languageEnglish

Abstract

Objectives Serum CA72-4 levels are elevated in some gout patients but this has not been comprehensively described. The present study profiled serum CA72-4 expression in gout patients and verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort. Methods To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty arthritis, asymptomatic hyperuricaemia, four major arthritis types (OA, RA, SpA, septic arthritis) and healthy controls. A prospective gout cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month follow-up, gout flares, CA72-4 levels and other gout-related clinical variables were observed at 1, 3 and 6 months. Results CA72-4 was highly expressed in patients with gouty arthritis [median (interquartile range) 4.55 (1.56, 32.64) U/ml] compared with hyperuricaemia patients [1.47 (0.87, 3.29) U/ml], healthy subjects [1.59 (0.99, 3.39) U/ml] and other arthritis patients [septic arthritis, 1.38 (0.99, 2.66) U/ml; RA, 1.58 (0.95, 3.37) U/ml; SpA, 1.56 (0.98, 2.85) U/ml; OA, 1.54 (0.94, 3.34) U/ml; P < 0.001, respectively]. Gout patients with frequent flares (twice or more in the last year) had higher CA72-4 levels than patients with fewer flares (fewer than twice in the last year). High CA72-4 level (>6.9 U/ml) was the strongest predictor of gout flares (hazard ratio = 3.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels (P = 0.014). Conclusion CA72-4 levels were upregulated in gout patients who experienced frequent flares and CA72-4 was a useful biomarker to predict future flares.

Bibliographic note

This is a pre-copy-editing, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The definitive publisher-authenticated version Xueshan Bai, Mingshu Sun, Yuwei He, Ruhua Liu, Lingling Cui, Can Wang, Fang Wan, Ming Wang, Xinde Li, Hailong Li, Xinjiang Wu, Changgui Li, Serum CA72-4 is specifically elevated in gout patients and predicts flares, Rheumatology, , keaa046, https://doi.org/10.1093/rheumatology/keaa046 is available online at: